ECSP045517A - Procedimiento para dejar de fumar - Google Patents
Procedimiento para dejar de fumarInfo
- Publication number
- ECSP045517A ECSP045517A EC2004005517A ECSP045517A ECSP045517A EC SP045517 A ECSP045517 A EC SP045517A EC 2004005517 A EC2004005517 A EC 2004005517A EC SP045517 A ECSP045517 A EC SP045517A EC SP045517 A ECSP045517 A EC SP045517A
- Authority
- EC
- Ecuador
- Prior art keywords
- procedure
- stop smoking
- quit smoking
- reboxetine
- revealed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se revela el uso de la reboxetina en combinación con un agente que ayuda a dejar de fumar. También se revela una composición que comprende reboxetina y un agente que ayuda a dejar de fumar. Ejemplos de los agentes que ayuda a dejar de fumar incluyen nicotina, un antidepresivo, un antagonista del receptor de nicotina, y un antagonista opiode.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39289302P | 2002-07-01 | 2002-07-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP045517A true ECSP045517A (es) | 2005-03-10 |
Family
ID=30000949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2004005517A ECSP045517A (es) | 2002-07-01 | 2004-12-28 | Procedimiento para dejar de fumar |
Country Status (22)
Country | Link |
---|---|
US (1) | US20040102440A1 (es) |
EP (1) | EP1534254A2 (es) |
JP (1) | JP2005531631A (es) |
CN (1) | CN1665511A (es) |
AP (1) | AP2004003188A0 (es) |
AU (1) | AU2003253609A1 (es) |
BR (1) | BR0312293A (es) |
CA (1) | CA2491549A1 (es) |
EA (1) | EA200401584A1 (es) |
EC (1) | ECSP045517A (es) |
HR (1) | HRP20041194A2 (es) |
IL (1) | IL165882A0 (es) |
IS (1) | IS7600A (es) |
MA (1) | MA27597A1 (es) |
MX (1) | MXPA05000296A (es) |
NO (1) | NO20045535L (es) |
OA (1) | OA12878A (es) |
PL (1) | PL373620A1 (es) |
RS (1) | RS115204A (es) |
TN (1) | TNSN04267A1 (es) |
WO (1) | WO2004002463A2 (es) |
ZA (1) | ZA200410339B (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE521512C2 (sv) | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
DE60313216T2 (de) | 2002-12-20 | 2008-01-03 | Niconovum Ab | Chemisch und physikalisch stabiles teilchenförmiges material enthaltend nikotin und microcrystalline cellulose |
JP4343948B2 (ja) | 2003-04-29 | 2009-10-14 | オレキシジェン・セラピューティクス・インコーポレーテッド | 体重減少に影響を及ぼすための組成物 |
EP1870096A3 (en) * | 2003-04-29 | 2011-04-20 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
NZ561375A (en) | 2005-06-27 | 2011-06-30 | Biovail Lab Int Srl | Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound |
CA2630624C (en) | 2005-11-22 | 2013-08-06 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
JP5694645B2 (ja) | 2006-03-16 | 2015-04-01 | ニコノヴァム エービーNiconovum Ab | 改善された嗅ぎたばこ組成物 |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
US20070297991A1 (en) * | 2006-06-23 | 2007-12-27 | Minu, L.L.C. | Neural conduit agent dissemination for smoking cessation and other applications |
KR20160072276A (ko) | 2006-11-09 | 2016-06-22 | 오렉시젠 세러퓨틱스 인크. | 단위 용량 팩키지 |
WO2009004621A1 (en) * | 2007-07-02 | 2009-01-08 | Technion Research & Development Foundation Ltd. | Compositions, articles and methods comprising tspo ligands for preventing or reducing tobacco-associated damage |
CA2725930A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
US20100069389A1 (en) * | 2008-09-06 | 2010-03-18 | Bionevia Pharmaceuticals, Inc. | Novel forms of reboxetine |
US20110046116A1 (en) | 2009-08-20 | 2011-02-24 | Cukrowski Walter J | Sedative for use during eye surgery |
CA2776160A1 (en) * | 2009-09-30 | 2011-04-07 | Harlan Clayton Bieley | Smoking cessation with body weight maintenance and nutritional supplement |
CN102724878A (zh) | 2010-01-11 | 2012-10-10 | 奥雷西根治疗公司 | 在重度抑郁症患者中提供体重减轻疗法的方法 |
TW201217526A (en) | 2010-07-09 | 2012-05-01 | Biogen Idec Hemophilia Inc | Chimeric clotting factors |
EA201492175A1 (ru) | 2012-06-06 | 2015-10-30 | Орексиджен Терапьютикс, Инк. | Способы лечения избыточного веса и ожирения |
WO2015054730A1 (en) * | 2013-10-14 | 2015-04-23 | Palmaya Pty Ltd | Compositions and methods of administering same |
US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
EP3082816B1 (en) | 2013-12-20 | 2019-03-20 | Indivior UK Limited | Intranasal naloxone compositions and methods of making and using same |
CN104381577A (zh) * | 2014-11-18 | 2015-03-04 | 安徽润康保健食品有限公司 | 一种具有戒烟功能的口香糖 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1301164A (zh) * | 1998-04-09 | 2001-06-27 | 法玛西雅厄普约翰美国公司 | 神经病症的新疗法 |
ATE283694T1 (de) * | 1998-05-08 | 2004-12-15 | Upjohn Co | Neue arzneimittelkombinationen aus reboxetin und pindolol |
DE60022692T2 (de) * | 1999-07-01 | 2006-06-22 | Pharmacia & Upjohn Co. Llc, Kalamazoo | (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen |
DE10004547A1 (de) * | 2000-02-02 | 2001-08-09 | Liedtke Pharmed Gmbh | Verfahren zur selektiven Verabreichung zentralnervös aktiver Stoffe |
-
2003
- 2003-06-24 US US10/602,447 patent/US20040102440A1/en not_active Abandoned
- 2003-06-26 AP AP200403187D patent/AP2004003188A0/xx unknown
- 2003-06-26 OA OA1200400348A patent/OA12878A/en unknown
- 2003-06-26 CN CN038156369A patent/CN1665511A/zh active Pending
- 2003-06-26 RS YUP-1152/04A patent/RS115204A/sr unknown
- 2003-06-26 EP EP03761901A patent/EP1534254A2/en not_active Ceased
- 2003-06-26 EA EA200401584A patent/EA200401584A1/ru unknown
- 2003-06-26 MX MXPA05000296A patent/MXPA05000296A/es not_active Application Discontinuation
- 2003-06-26 BR BR0312293-0A patent/BR0312293A/pt not_active IP Right Cessation
- 2003-06-26 AU AU2003253609A patent/AU2003253609A1/en not_active Abandoned
- 2003-06-26 JP JP2004517572A patent/JP2005531631A/ja active Pending
- 2003-06-26 CA CA002491549A patent/CA2491549A1/en not_active Abandoned
- 2003-06-26 PL PL03373620A patent/PL373620A1/xx not_active Application Discontinuation
- 2003-06-26 WO PCT/US2003/016232 patent/WO2004002463A2/en active Application Filing
-
2004
- 2004-12-16 HR HR20041194A patent/HRP20041194A2/xx not_active Application Discontinuation
- 2004-12-16 IS IS7600A patent/IS7600A/is unknown
- 2004-12-17 MA MA28018A patent/MA27597A1/fr unknown
- 2004-12-17 NO NO20045535A patent/NO20045535L/no not_active Application Discontinuation
- 2004-12-20 IL IL16588204A patent/IL165882A0/xx unknown
- 2004-12-22 ZA ZA200410339A patent/ZA200410339B/en unknown
- 2004-12-28 EC EC2004005517A patent/ECSP045517A/es unknown
- 2004-12-30 TN TNP2004000267A patent/TNSN04267A1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
CN1665511A (zh) | 2005-09-07 |
MXPA05000296A (es) | 2005-08-19 |
EP1534254A2 (en) | 2005-06-01 |
PL373620A1 (en) | 2005-09-05 |
AU2003253609A1 (en) | 2004-01-19 |
OA12878A (en) | 2006-09-15 |
JP2005531631A (ja) | 2005-10-20 |
EA200401584A1 (ru) | 2005-08-25 |
MA27597A1 (fr) | 2005-11-01 |
IL165882A0 (en) | 2006-01-15 |
BR0312293A (pt) | 2005-04-12 |
AP2004003188A0 (en) | 2004-12-31 |
HRP20041194A2 (en) | 2005-06-30 |
WO2004002463A3 (en) | 2004-02-19 |
CA2491549A1 (en) | 2004-01-08 |
IS7600A (is) | 2004-12-16 |
ZA200410339B (en) | 2006-07-26 |
WO2004002463A2 (en) | 2004-01-08 |
US20040102440A1 (en) | 2004-05-27 |
RS115204A (en) | 2007-02-05 |
NO20045535L (no) | 2005-01-27 |
TNSN04267A1 (fr) | 2007-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP045517A (es) | Procedimiento para dejar de fumar | |
ECSP088131A (es) | Asociación de un agente hipnótico de duración de acción larga y un agente hipnótico de duración de acción corta y su aplicación en terapéutica | |
EE200300033A (et) | Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon | |
UY27465A1 (es) | Métodos y composiciones para tratar flavivirus y pestivirus con 4' modificaciones nucleosides | |
ES2167061T3 (es) | Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino. | |
PE20020968A1 (es) | Preparados de insulina exentos de zinc y pobres en zinc, con estabilidad mejorada | |
AR028505A1 (es) | Utilizacion de un antagonista de los receptores de cannabinoides centrales para la preparacion de medicamentos utiles para que sea mas frcil detener el consumo de tabaco | |
PE20060594A1 (es) | Composicion farmaceutica que contiene un agonista de ppar | |
CL2009001025A1 (es) | Composicion de pastilla para chupar que comprende: a) un granulo patron con al menos: un agente tampon alcalino, un modificador de la disolucion y una carga, b) un principio activo de nicotina definido extragranular y al menos un agente tampon alcalino; procedimiento de preparacion; util para eliminar o reducir el uso de tabaco. | |
CL2008002407A1 (es) | Forma de dosificacion oral que comprende al menos un agente activo de nicotina, al menos un material bioadhesivo capaz de formar un enlace de hidrogeno con el agente activo de nicotina, y al menos un agente de impacto sensorial que se libere rapidamente; y su uso para proporcionar alivio rapido de las ansias de nicotina (div. sol. 1825-04). | |
NO20024309D0 (no) | Intradermal penetreringsmidler for topikal lokal anestetisk administrering | |
HN2006007884A (es) | Derivados de oxiindol | |
BRPI0514474A (pt) | multiparticulados | |
DE60232417D1 (de) | Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist | |
CO5190708A1 (es) | Mezcla sinergica para el tratamiento del sindrome de piernas inquietas | |
AR036266A1 (es) | Pelicula para refrescar el aliento | |
AR062860A1 (es) | Combinaciones terapeuticas 482 | |
PA8502901A1 (es) | Tratamiento de combinacion con il-1ra y compuestos que inhiben el procesamiento y la liberacion de il-1 | |
CY1104971T1 (el) | Παρασκευασμα αποϊνιδοτιδιου και g-csf και η χρηση του για να κινητοποιει αιμοποιητικους προγονους | |
CL2008001072A1 (es) | Bloque de limpieza de inodoro que es al menos parcialmente transparente o translucida, que comprende 2 - 50% de material biocida y 50 - 98% de composicion portadora que comprende 5 - 50% de agente jabon, 30 - 90% de humectante, 5 - 30% de solvente; metodo para proporcionar higiene en un inodoro; y uso del bloque | |
PE20010577A1 (es) | Composicion farmaceutica para la prevencion y tratamiento de la adiccion a la nicotina que comprende un agonista del receptor nicotinico, un agente antidepresivo o ansiolitico | |
AR043422A1 (es) | Envase que contiene nicotina, uso y fabricacion | |
AR028502A1 (es) | Tratamiento de condiciones inflamatorias alérgicas | |
AR029092A1 (es) | Composiciones para el tratamiento del cabello | |
UY27031A1 (es) | Uso de agonistas selectivos del receptor de dopamina d4 para tratar disfunción sexual |